[PFE] Pfizer: Q3 2026 earnings preview on COVID sales and Eliquis pricing

Pfizer is a large U.S. research-based drugmaker that develops, manufactures and sells innovative medicines and vaccines[1]. The company is scheduled to hold its earnings call on 2026-11-03 to report results for the third quarter of 2026[2]. In the latest disclosed period, the second quarter ended June 28, 2026, revenue rose 3% year over year to $15.034 billion[3]; excluding COVID products, revenue grew 5% operationally, adjusted EPS was $0.77, adjusted gross margin was about 76%, and large impairments produced a GAAP loss of $0.04 per share[4]. On August 4 Pfizer raised its 2026 revenue guidance to $60.5 billion-$62.5 billion, kept adjusted EPS guidance at $2.80-$3.00 and cut its full-year COVID revenue outlook from about $5 billion to about $4 billion[5]; against first-half revenue of $29.484 billion and adjusted EPS of $1.52, the second half needs $31 billion-$33 billion of revenue and $1.28-$1.48 of adjusted EPS[6][7]. As of October 14, the consensus compiled by Drillr from 9 analysts put third-quarter revenue at $15.889 billion, and 11 analysts put adjusted EPS at $0.73[8]; 14 analysts put full-year EPS at $2.96, close to the top of company guidance[9].

Three things matter most in the third-quarter report. First, COVID products need to show enough progress in the fall vaccination season: Comirnaty and Paxlovid sold only $700 million combined in the first half, the roughly $4 billion full-year outlook implies about $3.3 billion in the second half, and a third-quarter total well below $1.3 billion could offset the guidance raise that the non-COVID portfolio earned in August[6][10]. Second, U.S. Eliquis revenue needs to hold the second quarter's $1.651 billion: after Medicare's negotiated price took effect in January, U.S. revenue still rose 25% in the second quarter, which Pfizer attributed to lower rebates and a more favorable channel mix, so the third quarter has to show whether that was a durable net-price improvement or a one-time adjustment[11][12]. Third, adjusted EPS needs to stay within the $0.64-$0.74 per quarter implied by full-year guidance: R&D expense rose 13% in the second quarter, adjusted EPS of $0.77 was already slightly below the prior-year $0.78, and a COVID revenue rebound would dilute gross margin, so whether gross margin holds above 75% decides whether cost cuts can offset the heavier R&D spending[13][14][15].

Company Background and Business Structure

Pfizer's business is concentrated almost entirely in innovative medicines and vaccines. Its operating segments include Biopharma and PC1: Biopharma researches, manufactures and sells innovative medicines and vaccines and is the only reportable segment, while PC1 is a contract development and manufacturing business that also supplies specialty active pharmaceutical ingredients; in 2025 Pfizer decided to discontinue Pfizer Ignite, which had provided R&D services to outside biotech companies[1]. Comirnaty and Paxlovid pushed revenue to a peak during the pandemic before COVID sales fell quickly; management said Pfizer has placed more than $80 billion in large business-development deals since 2022, the three largest being antibody-drug-conjugate developer Seagen, obesity-drug developer Metsera and Biohaven[10], and the Metsera acquisition closed in November 2025 for consideration with a fair value of about $8 billion[16].

Biopharma is organized into portfolios such as primary care, specialty care and oncology, and revenue is concentrated in a few large products. In 2025 primary care generated $26.820 billion, including Eliquis at $7.961 billion (of which $5.148 billion in the U.S.), the Prevnar family at $6.494 billion, Comirnaty at $4.367 billion, Paxlovid at $2.362 billion, migraine drug Nurtec at $1.424 billion and RSV vaccine Abrysvo at $1.033 billion[17][18]. In the same year specialty care generated $17.546 billion, led by the Vyndaqel family at $6.380 billion, and oncology generated $16.834 billion, including Ibrance at $4.122 billion, Xtandi (partnered with Astellas) at $2.194 billion, Padcev at $1.940 billion, oncology biosimilars at $1.301 billion and Lorbrena at $1.023 billion[17].

Channel and partnership structures determine Pfizer's U.S. net pricing and how profits are shared. In the U.S. Pfizer sells mainly through three wholesalers, and in 2025 McKesson, Cencora and Cardinal Health accounted for 25%, 16% and 13% of total revenue[19]; products then flow to pharmacies, hospitals and clinics and are ultimately paid for by Medicare, Medicaid, commercial insurers and foreign government health systems. Gross sales are reduced by rebates, chargebacks, allowances and returns, which totaled $36.374 billion in 2025, including $4.511 billion of Medicare rebates[20], so U.S. net prices are highly sensitive to payer contracts, government pricing and channel mix. Some products are booked as alliance revenue: Pfizer shares Eliquis profits and losses equally with Bristol Myers Squibb in most markets[21], splits Comirnaty gross profit with BioNTech[22], and co-develops and sells Xtandi with Astellas, which holds exclusive commercialization rights outside the U.S.[23]; COVID products are strongly seasonal, and most of Comirnaty's 2025 global revenue was recorded in the fourth quarter[24].

Financial History and Current Position

Pfizer's annual revenue has settled at roughly $60 billion since the pandemic peak. Total revenue was $59.553 billion in 2023, $63.627 billion in 2024 and $62.579 billion in 2025[17]; the 2% decline in 2025 came mainly from a $3.346 billion drop in Paxlovid and a $1.051 billion drop in Comirnaty, and excluding those two products revenue grew 6% operationally[25][26]. In 2025 GAAP net income attributable to Pfizer was $7.771 billion, or $1.36 per diluted share, and adjusted EPS excluding items such as intangible amortization was $3.22[27].

By 2025 operating cash flow was no longer enough to cover both dividends and capital spending. Operating cash flow for the year was $11.704 billion, capital expenditure was $2.629 billion and dividends paid were $9.771 billion, and Pfizer also paid $6.927 billion in cash for Metsera[28]; long-term debt stood at $61.641 billion at year-end[29].

Revenue returned to growth in the first half of 2026, but one-time impairments sharply depressed GAAP profit. First-half revenue rose 4% to $29.484 billion[6], and second-quarter revenue rose 3% to $15.034 billion[3]. Pfizer reported a second-quarter GAAP net loss attributable to the company of $248 million[30], driven mainly by a $3.8 billion in-process R&D impairment after the failed Phase 3 trial of sigvotatug vedotin, a $525 million impairment after Oxbryta was found to have no viable path back to the U.S. market, and legal expenses[31]; adjusted EPS was $0.77 for the quarter and $1.52 for the first half, below $1.69 a year earlier[14][7].

First-half cash flow also failed to cover the dividend, and balance-sheet leverage is not set to fall soon. Operating cash flow for the first half of 2026 was $3.450 billion[32], capital expenditure was $969 million and dividends paid were $4.896 billion[33], with no share repurchases[34]. On June 28, cash and short-term investments totaled $11.699 billion and long-term debt was $60.495 billion[35]; management said leverage ended the second quarter at about 2.7 times and is expected to stay near that level through the patent-expiry transition[36].

Operating Model

Pfizer's revenue is set by prescription volume, U.S. net prices and the seasonality of COVID products. Total revenue consists of product revenue, alliance revenue, royalty revenue and PC1 contract manufacturing revenue, and in the second quarter of 2026 product revenue was $11.863 billion, alliance revenue $2.697 billion and royalty revenue $474 million[30]; each product's revenue equals prescriptions or vaccinations times net price, where net price is list price minus rebates, chargebacks, allowances and returns[20]. U.S. Eliquis revenue depends on anticoagulant prescription volume, the Medicare negotiated price effective January 2026, commercial rebates and channel mix[12][11]; Vyndaqel revenue depends on the number of diagnosed ATTR-CM patients who stay on therapy and on U.S. net prices shaped by new payer contracts[37]; COVID revenue depends on fall and winter vaccinations, infection-driven prescriptions and deliveries under foreign government contracts, and is concentrated in the second half, especially the fourth quarter[38][24]. In-line products excluding COVID are growing about 5%-6% operationally, but Pfizer expects about $1.1 billion of 2026 revenue to be affected by patent or exclusivity expiries[4][39].

Adjusted profit depends on the trade-off between product mix, the pace of cost cuts and R&D investment. Adjusted income equals revenue minus adjusted cost of sales, adjusted selling, informational and administrative expenses (SI&A), R&D and acquired in-process R&D, plus other income, less taxes, divided by about 5.7 billion shares; in the second quarter adjusted cost of sales was $3.656 billion, adjusted SI&A was $3.344 billion and adjusted EPS was $0.77[14], while GAAP R&D expense was $2.809 billion[30]. Gross margin is driven mainly by mix: Pfizer splits COVID gross profit with BioNTech and Eliquis profits with Bristol Myers Squibb, so the higher the share of wholly owned patented drugs, the higher the margin[22][21]. The cost program is set to deliver about $5.7 billion of cumulative net savings by the end of 2026, while the additional $1 billion of SI&A savings and $1.5 billion of manufacturing savings announced in August start to show only from 2027, so they will not improve third-quarter 2026 profit[40].

Cash flow is distorted by impairments and tax payments, and Pfizer prioritizes the dividend in its use of cash. Operating cash flow equals net income plus depreciation, amortization and non-cash impairments, less working capital and tax outflows; it was $11.704 billion in 2025 and $3.450 billion in the first half of 2026[28][32]. Pfizer directs cash first to R&D, business development and a quarterly dividend of $0.43 per share, repaid $1.25 billion of long-term debt in the first half[33], is not buying back stock and has $3.3 billion of remaining repurchase authorization, and received $1.875 billion in cash from selling its ViiV stake[34]. Government prepayments for COVID products create deferred revenue, which stood at $1.4 billion at the end of June; it turns into revenue on delivery but brings no new cash[41].

Industry and Competitive Position

Pfizer faces branded competition, generic and biosimilar erosion, and new products in vaccines at the same time. Its 10-K says competition centers on efficacy, safety, tolerability, ease of use and cost[42], and growing competition in vaccines is forcing larger discounts[43]; second-quarter Prevnar family revenue was $1.337 billion, down from $1.383 billion a year earlier[6]. Several in-line products will lose patent or regulatory exclusivity between 2026 and 2030; Pfizer initially expected a $1.5 billion revenue impact in 2026[44], revised that to about $1.1 billion in the second quarter, and said the impact will accelerate significantly over the next few years[39].

U.S. drug-pricing policy is a second constraint beyond competition, and Pfizer is responding mainly with new products, its pipeline and cost cuts. The Medicare negotiated price for Eliquis took effect on January 1, 2026, and negotiated prices for Ibrance and Xtandi take effect in 2027[45], while the 2025 Medicare Part D redesign already reduced revenue by about $1 billion[46]. Pfizer's response includes launched and acquired products (second-quarter revenue of $3.2 billion, up 18% operationally)[4], its oncology and obesity pipelines, and a net cost-savings target totaling about $9.7 billion through 2029[36]. Because Pfizer does not disclose product profits, prescription volumes or U.S. net prices, any comparison with peers is limited to revenue scale and the company's qualitative explanations.

Core Debates

Pfizer has already cut its 2026 COVID revenue outlook from $5 billion to $4 billion, yet it sold only $700 million in the first half. Once the fall vaccination season starts, can the third quarter deliver enough progress to make $4 billion a floor rather than the start of another cut?

COVID revenue determines whether the August guidance raise holds. COVID products still contributed $6.729 billion in 2025, about 10.7% of total revenue[17]; the roughly $4 billion full-year outlook requires about $3.3 billion in the second half, about $1.7 billion less than the roughly $4.866 billion of the second half of 2025, and another cut would offset the guidance raise earned by non-COVID products[4][6]. Second-quarter data were weak: Comirnaty revenue fell 34% to $261 million, with only $38 million in the U.S., which the 10-Q attributed to smaller favorable returns-reserve adjustments and narrower U.S. vaccination recommendations[47]; Paxlovid fell 95% to $21 million on fewer infections and lower foreign government purchases[48].

The numeric baseline and revenue phasing for COVID products shape how the third quarter should be read. COVID products totaled $282 million in the second quarter and $700 million in the first half[6]; the 10-K said most of Comirnaty's 2025 global revenue was recorded in the fourth quarter, and Pfizer expects similar phasing in 2026[24], while management said vaccine revenue is driven mainly by perceived risk and Paxlovid tracks annual infection rates closely[10]. The financial chain runs from the scope of U.S. vaccination recommendations and infection levels to fall vaccination volume and Paxlovid prescriptions, then to wholesaler and pharmacy orders and deliveries under foreign government contracts, and finally to revenue for the two products and returns-reserve adjustments; because Comirnaty gross profit is split with BioNTech, a revenue shortfall hits EPS less than it hits revenue[22].

The debate is unresolved because a weak third quarter could mean either worsening demand or simply revenue concentrated in the fourth quarter. The alternative view is that the August $4 billion already reflects low infection rates, so a soft third quarter would not signal further deterioration; telling the two apart depends on whether the full-year outlook holds and whether U.S. Comirnaty recovers from its second-quarter low. The third-quarter report should show whether combined COVID revenue reaches at least $1.3 billion, whether the full-year outlook stays at about $4 billion, whether U.S. Comirnaty is clearly above $38 million, and whether Paxlovid exceeds its first-half total of $207 million[6]. Another cut to the full-year outlook would show that narrower U.S. recommendations and low infection rates are still widening their impact; third-quarter COVID revenue below $1 billion with an unchanged outlook would sharply raise the delivery burden on the fourth quarter.

Medicare's negotiated price for Eliquis took effect in January, yet U.S. Eliquis revenue rose 25% in the second quarter, which Pfizer attributed to lower rebates and a more favorable channel mix. Will that net-price improvement persist into the third quarter, or was it a one-time effect?

U.S. Eliquis net pricing is the most direct single variable in Pfizer's profit. Eliquis is Pfizer's largest product, contributing $2.425 billion in the second quarter, about 16% of quarterly revenue, and U.S. revenue was $329 million higher than a year earlier[11], twice the company's $164 million operational revenue increase for the quarter[3]. Pfizer shares Eliquis profits and losses equally with Bristol Myers Squibb in most markets, so changes in U.S. net price flow fairly directly into profit[21].

The difference in growth between the first two quarters came mainly from pricing rather than demand. U.S. revenue rose 10% to $1.435 billion in the first quarter, when Pfizer cited only demand growth[49]; in the second quarter it rose 25% to $1.651 billion, which Pfizer attributed to lower rebates, a favorable channel mix and global demand, with global revenue up 19% operationally and international revenue at $773 million[11]. First-quarter global revenue was $2.166 billion[50]; the 10-K showed lower U.S. net prices and higher demand in 2025[18], and the Medicare negotiated price has applied since January 1, 2026[12]. The financial chain runs from the Medicare negotiated price, commercial rebate contracts and channel mix to U.S. net price, and from anticoagulant prescriptions to volume; together they form U.S. revenue, which flows through the Bristol Myers Squibb split into alliance revenue, primary-care revenue and adjusted EPS.

It is not yet clear whether the second-quarter net-price improvement will last. The alternative explanation is that the second quarter included rebate-accrual adjustments or channel inventory changes and that the third quarter will revert toward first-quarter levels; the third-quarter U.S. revenue level and the 10-Q's wording will separate the two. The report should show whether U.S. revenue is at least $1.600 billion, whether global operational growth is at least 14%, whether the 10-Q still attributes U.S. growth to lower rebates and channel mix, and whether international revenue keeps growing operationally. U.S. revenue back below $1.435 billion would show that the second-quarter improvement was mostly one-time; on patents, settled generics may launch on April 1, 2028, but an adverse ruling on the formulation patent could allow generics as early as November 21, 2026[23].

U.S. Vyndaqel revenue fell 8% in the first quarter after new payer contracts cut net prices, then rebounded 7% in the second quarter on more patients. Can the U.S. hold that rebound in the third quarter, and is slowing international growth an early sign that exclusivity is loosening?

Vyndaqel is an important pillar of Pfizer's growth and gross margin. The Vyndaqel family generated $6.380 billion in 2025 and was one of the year's largest sources of incremental revenue[18]. It is a wholly owned patented drug with higher margins than alliance products, so changes in its growth move gross margin and EPS more than the same amount of COVID revenue.

U.S. price and patient volume are pulling against each other, and international growth has slowed sharply. First-quarter U.S. revenue fell 8% to $911 million, which the 10-Q attributed to net-price erosion from new payer contracts partly offset by market expansion[37]; in the second quarter U.S. revenue rose 7% to $1.064 billion on market expansion, though the 10-Q still cited net-price erosion, global revenue was $1.762 billion, up 8% operationally, and international revenue was $698 million, up 8% operationally, well below the first quarter's 26%[51]. On exclusivity, Pfizer has settled U.S. litigation with all generic filers except Apotex, with generic Vyndamax launching in June 2031[52]; the basic European patent expires in 2026[53], but the European Medicines Agency refused to validate Teva's generic application, and Teva has sued over that decision[54]. The financial chain runs from ATTR-CM diagnosis and treatment penetration to the number of patients on therapy, from new U.S. payer contracts and competition to net price, and from European and Japanese patents or exclusivity to the timing of generic entry abroad, which together shape specialty-care revenue, the share of high-margin products and adjusted gross margin.

The nature of the international slowdown remains open. The alternative view is that it reflects only first-quarter comparisons and delivery timing, and that the U.S. rebound is normal growth after a one-time contract price reset; whether the U.S. holds in the third quarter and whether international growth keeps slowing will separate the two. The report should show whether U.S. revenue is at least $1.064 billion, whether global operational growth is at least 6%, whether international operational growth stays below 10%, and whether the 10-Q discloses new developments in the Apotex case or European generics. U.S. revenue below $1 billion would show that price pressure is outrunning patient growth; generic tafamidis in Europe would hit international revenue first.

Pfizer is raising R&D spending by 13% to fund oncology and obesity while cutting selling and administrative costs. With rising COVID revenue likely to dilute gross margin in the third quarter, can adjusted EPS stay within the range implied by its $2.80-$3.00 full-year guidance?

Full-year EPS guidance leaves little room for the second half. Subtracting first-half results from full-year guidance leaves $0.64-$0.74 of adjusted EPS needed per quarter in the second half[5][7], and the third-quarter consensus of $0.73 sits near the top of that range[8]. Second-quarter EPS of $0.77 was already below $0.78 a year earlier[14][15], which shows that cost cuts are only offsetting higher R&D and patent expiries.

The second-quarter cost structure shows cost cuts and heavier R&D roughly offsetting each other. Adjusted cost of sales was $3.656 billion, giving an adjusted gross margin of about 75.7% on $15.034 billion of revenue (76% as stated on the call), compared with about 76.1% for the first half and about 78.5% a year earlier[14][7]; adjusted SI&A was $3.344 billion versus $3.395 billion a year earlier[15]; R&D expense rose 13% to $2.809 billion, including about $240 million more for oncology and obesity candidates[13], and adjusted operating margin was about 35%[4]. The additional $1 billion of SI&A savings and $1.5 billion of manufacturing savings announced in August both start to show from 2027[40]. The financial chain runs from cost programs in SI&A and manufacturing and from oncology and obesity R&D spending to adjusted gross margin, SI&A and R&D expense, then to adjusted operating profit, and after adjusted taxes and division by about 5.7 billion shares to adjusted EPS.

Weak third-quarter EPS would not necessarily mean the guidance is in trouble. The alternative view is that a soft third quarter reflects only the concentration of COVID revenue in the fourth quarter and that the full year will still land within guidance; whether gross margin holds above 75% and whether full-year guidance is maintained will separate the two. The report should show whether adjusted EPS is at least $0.74, whether the $2.80-$3.00 full-year guidance is maintained, whether adjusted gross margin is at least 75%, and whether adjusted SI&A is no higher than $3.344 billion. Adjusted EPS below $0.64 would show that cost savings are not keeping pace with higher R&D and mix shifts; gross margin below 74% would show that pressure from low-margin COVID and alliance products is greater than the guidance assumed.

Risks and Falsifiers

Tighter U.S. drug-pricing policy would directly lower net prices for oncology products. Medicare negotiated prices for Ibrance and Xtandi take effect in 2027[45], and management said on the call that a proposed 340B hospital reimbursement cut could affect oncology revenue[55]; the exposure is 2025 oncology revenue of $16.834 billion, including Ibrance at $4.122 billion and Xtandi at $2.194 billion[17], while the 2025 Medicare Part D redesign already cut revenue by about $1 billion[46]. The concern would ease if the third-quarter 10-Q adds no new policy impact on 2026 revenue and the 340B cut is not implemented.

Cash flow does not cover dividends and capital spending, and together with pipeline impairments and legal costs, this makes it hard for leverage to fall during the patent-expiry transition. Operating cash flow of $11.704 billion in 2025 was below the sum of $9.771 billion in dividends and $2.629 billion in capital expenditure[28]; operating cash flow of $3.450 billion in the first half of 2026 was also below $4.896 billion in dividends[33], long-term debt was $60.495 billion[35], leverage was about 2.7 times[36], and the second quarter included a $3.8 billion in-process R&D impairment[31]. The risk would be falsified if second-half operating cash flow exceeds dividends plus capital expenditure for the period and management maintains the dividend without raising its leverage expectations.

Narrower U.S. vaccination recommendations and low infection rates could keep fall and winter COVID demand below Pfizer's August assumptions. The exposure is Comirnaty and Paxlovid within primary care, with a full-year outlook of about $4 billion and about $3.3 billion implied for the second half[4]; every $500 million shortfall equals about 0.8% of the full-year revenue guidance midpoint, and U.S. Comirnaty was only $38 million in the second quarter[47]. The risk would be falsified if third-quarter COVID revenue is at least $1.3 billion and the full-year outlook stays at about $4 billion.

The second-quarter improvement in U.S. Eliquis net price could prove to be a one-time rebate accrual or channel-timing effect, while patent challenges could bring generics in early. The exposure is $1.651 billion of second-quarter U.S. Eliquis revenue[11]; a return to first-quarter levels would mean about $220 million less revenue per quarter, with roughly half that impact on profit under the equal profit split[21]. The risk would be falsified if third-quarter U.S. Eliquis revenue is at least $1.600 billion and the 10-Q keeps the settled April 1, 2028 generic entry date[23].

Continued U.S. payer price cuts and earlier loss of exclusivity abroad could stall Vyndaqel's growth. The exposure is the Vyndaqel family within specialty care, with $6.380 billion of revenue in 2025[18]; every 5-point drop in global growth means about $320 million less annual revenue on the 2025 base, and litigation over a European generic application is still pending[54]. The risk would be falsified if third-quarter U.S. revenue is at least $1.064 billion, global operational growth is at least 6% and no new generic enters.

R&D growth and mix shifts could outpace cost cuts and push adjusted margins lower. The exposure is adjusted operating profit and EPS, with full-year guidance of $2.80-$3.00[5]; each 1-point drop in adjusted gross margin on about $15.5 billion of quarterly revenue means about $150 million less gross profit, or about $0.02 of EPS, and second-quarter R&D expense already rose 13%[13]. The risk would be falsified if third-quarter adjusted EPS is at least $0.74, gross margin is at least 75% and full-year guidance is maintained.

What to Watch Next

• Fall COVID revenue: combined Comirnaty and Paxlovid revenue was $282 million in the second quarter and $700 million in the first half, against a full-year outlook of about $4 billion. At least $1.3 billion in the third quarter with the outlook maintained would confirm it; another cut or a total below $1 billion would weaken it.
• U.S. Eliquis net price: U.S. revenue was $1.651 billion in the second quarter (up 25%) and $1.435 billion in the first. At least $1.600 billion with unchanged attribution in the 10-Q would confirm it; a return below $1.435 billion would falsify it.
• Vyndaqel price and exclusivity: U.S. revenue was $1.064 billion in the second quarter and international growth was 8% operationally. U.S. revenue of at least $1.064 billion with global growth of at least 6% would confirm it; U.S. revenue below $1 billion would weaken it.
• Cost versus R&D: second-quarter adjusted EPS was $0.77, adjusted gross margin about 76% and adjusted SI&A $3.344 billion. EPS of at least $0.74 with gross margin of at least 75% would confirm it; EPS below $0.64 or gross margin below 74% would weaken it.

Conclusion

Pfizer's results are driven by three forces: operational growth in its non-COVID in-line products, seasonal delivery of COVID products, and the trade-off between cost cuts and R&D investment. First-half 2026 revenue rose 4% to $29.484 billion[6], adjusted EPS was $1.52, below $1.69 a year earlier[7], first-half operating cash flow of $3.450 billion fell short of the $4.896 billion paid in dividends[33], and long-term debt was $60.495 billion[35]. The key unresolved relationship is whether growth from Eliquis and newer products can cover the lower COVID outlook, patent expiries and heavier R&D so that the $2.80-$3.00 full-year adjusted EPS guidance is delivered in the second half[5].

Since the second-quarter report, public coverage has consisted mainly of recaps of results, dividend and insider-purchase announcements, pipeline and approval news, and reports on state attorney general lawsuits, with no verifiable outside interpretation that offers independent reasoning, so no outside view on these debates can be summarized here. Readers can rely only on the company's own disclosures and on the gap between company guidance and third-party compiled figures.

If third-quarter COVID revenue reaches at least $1.3 billion, U.S. Eliquis revenue is at least $1.600 billion, U.S. Vyndaqel revenue holds $1.064 billion, adjusted gross margin is at least 75% and full-year guidance is maintained, the current reading that the non-COVID business is providing a floor and cost cuts are offsetting R&D would strengthen materially. Conversely, another cut to the COVID outlook, U.S. Eliquis back below $1.435 billion, or adjusted EPS below $0.64 would show that the second-quarter improvement came largely from one-time factors and that profit pressure during the patent-expiry transition is greater than the August guidance reflected.

Sources

[1] PFE 10-K filed 2026-02-26 · commercial operations and segments · 2026-02-26 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-K&dateb=&owner=include&count=40

[2] Drillr earnings calendar (updated 2026-10-14) · PFE 2026-11-03 call · 2026-10-14 · earnings calendar · https://gateway.drillr.ai/mcp/private

[3] PFE 10-Q filed 2026-08-04 · Q2 2026 performance · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[4] PFE Q2 2026 earnings call 2026-08-04 · results summary · 2026-08-04 · earnings-call · https://gateway.drillr.ai/mcp/private

[5] PFE Q2 2026 earnings call 2026-08-04 · revenue and EPS guidance · 2026-08-04 · earnings-call · https://gateway.drillr.ai/mcp/private

[6] PFE 10-Q filed 2026-08-04 · Q2 2026 revenues by product · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[7] PFE 10-Q filed 2026-08-04 · H1 2026 adjusted income reconciliation · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[8] Drillr analyst_financial_estimates (updated 2026-10-14) · PFE quarter ending 2026-09-28 · 2026-10-14 · Drillr analyst_financial_estimates · https://gateway.drillr.ai/mcp/private

[9] Drillr analyst_financial_estimates (updated 2026-10-14) · PFE fiscal year 2026 · 2026-10-14 · Drillr analyst_financial_estimates · https://gateway.drillr.ai/mcp/private

[10] PFE Q2 2026 earnings call 2026-08-04 · COVID outlook Q&A · 2026-08-04 · earnings-call · https://gateway.drillr.ai/mcp/private

[11] PFE 10-Q filed 2026-08-04 · Q2 2026 Eliquis discussion · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[12] PFE 10-K filed 2026-02-26 · IRA Medicare price negotiation · 2026-02-26 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-K&dateb=&owner=include&count=40

[13] PFE 10-Q filed 2026-08-04 · Q2 2026 R&D expenses · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[14] PFE 10-Q filed 2026-08-04 · Q2 2026 adjusted income reconciliation · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[15] PFE 10-Q filed 2026-08-04 · Q2 2025 adjusted income reconciliation · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[16] PFE 10-K filed 2026-02-26 · Metsera acquisition · 2026-02-26 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-K&dateb=&owner=include&count=40

[17] PFE 10-K filed 2026-02-26 · revenues by product 2023-2025 · 2026-02-26 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-K&dateb=&owner=include&count=40

[18] PFE 10-K filed 2026-02-26 · 2025 selected product discussion · 2026-02-26 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-K&dateb=&owner=include&count=40

[19] PFE 10-K filed 2026-02-26 · wholesaler concentration · 2026-02-26 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-K&dateb=&owner=include&count=40

[20] PFE 10-K filed 2026-02-26 · product revenue deductions · 2026-02-26 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-K&dateb=&owner=include&count=40

[21] PFE 10-K filed 2026-02-26 · Eliquis alliance economics · 2026-02-26 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-K&dateb=&owner=include&count=40

[22] PFE 10-K filed 2026-02-26 · 2025 cost of sales and SI&A · 2026-02-26 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-K&dateb=&owner=include&count=40

[23] PFE 10-K filed 2026-02-26 · Eliquis and tafamidis patent notes · 2026-02-26 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-K&dateb=&owner=include&count=40

[24] PFE 10-K filed 2026-02-26 · Comirnaty revenue phasing · 2026-02-26 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-K&dateb=&owner=include&count=40

[25] PFE 10-K filed 2026-02-26 · 2025 performance · 2026-02-26 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-K&dateb=&owner=include&count=40

[26] PFE 10-K filed 2026-02-26 · 2025 revenue change by product · 2026-02-26 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-K&dateb=&owner=include&count=40

[27] PFE 10-K filed 2026-02-26 · 2025 adjusted income reconciliation · 2026-02-26 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-K&dateb=&owner=include&count=40

[28] PFE 10-K filed 2026-02-26 · 2025 cash flows · 2026-02-26 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-K&dateb=&owner=include&count=40

[29] PFE 10-K filed 2026-02-26 · balance sheet December 2025 · 2026-02-26 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-K&dateb=&owner=include&count=40

[30] PFE 10-Q filed 2026-08-04 · Q2 2026 income statement · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[31] PFE 10-Q filed 2026-08-04 · Q2 2026 impairments · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[32] PFE 10-Q filed 2026-08-04 · H1 2026 cash flow summary · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[33] PFE 10-Q filed 2026-08-04 · H1 2026 cash flow statement · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[34] PFE 10-Q filed 2026-08-04 · capital allocation and dividends · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[35] PFE 10-Q filed 2026-08-04 · balance sheet June 2026 · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[36] PFE Q2 2026 earnings call 2026-08-04 · cost programs and capital allocation · 2026-08-04 · earnings-call · https://gateway.drillr.ai/mcp/private

[37] PFE 10-Q filed 2026-05-05 · Q1 2026 Vyndaqel discussion · 2026-05-05 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-Q&dateb=&owner=include&count=40

[38] PFE 10-Q filed 2026-08-04 · Q2 2026 cost of sales and seasonality · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[39] PFE 10-Q filed 2026-08-04 · 2026 exclusivity-expiry outlook · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[40] PFE 10-Q filed 2026-08-04 · expanded cost programs · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[41] PFE 10-Q filed 2026-08-04 · COVID deferred revenues · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[42] PFE 10-K filed 2026-02-26 · competition · 2026-02-26 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-K&dateb=&owner=include&count=40

[43] PFE 10-K filed 2026-02-26 · vaccine competition and discounts · 2026-02-26 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-K&dateb=&owner=include&count=40

[44] PFE 10-K filed 2026-02-26 · 2026 exclusivity-expiry impact · 2026-02-26 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-K&dateb=&owner=include&count=40

[45] PFE 10-Q filed 2026-08-04 · IRA status at Q2 2026 · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[46] PFE 10-K filed 2026-02-26 · Part D redesign impact · 2026-02-26 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-K&dateb=&owner=include&count=40

[47] PFE 10-Q filed 2026-08-04 · Q2 2026 Comirnaty discussion · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[48] PFE 10-Q filed 2026-08-04 · Q2 2026 Paxlovid discussion · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[49] PFE 10-Q filed 2026-05-05 · Q1 2026 Eliquis discussion · 2026-05-05 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-Q&dateb=&owner=include&count=40

[50] PFE 10-Q filed 2026-05-05 · Q1 2026 revenues by product · 2026-05-05 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-Q&dateb=&owner=include&count=40

[51] PFE 10-Q filed 2026-08-04 · Q2 2026 Vyndaqel discussion · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[52] PFE 10-Q filed 2026-08-04 · Vyndaqel patent settlements · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[53] PFE 10-K filed 2026-02-26 · patent expiration table · 2026-02-26 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-K&dateb=&owner=include&count=40

[54] PFE 10-Q filed 2026-08-04 · Teva generic tafamidis EU suit · 2026-08-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/

[55] PFE Q2 2026 earnings call 2026-08-04 · stated risks · 2026-08-04 · earnings-call · https://gateway.drillr.ai/mcp/private